metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-worl...
Journal Information
Vol. 48. Issue 4.
Pages 295-303 (May 2024)
Share
Share
Download PDF
More article options
Vol. 48. Issue 4.
Pages 295-303 (May 2024)
Original article
Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study
Tislelizumab, un nuevo anticuerpo monoclonal anti-PD-1 para el cáncer urotelial: estudio de vida real
Z. Wang, H. Bi, Y.D. Wang, Q. Liu, B. Shao, C.Q. Li, C. Fu, S. Fu, G.Y. Shan, A. Chen, C.C. Lv, Y. Zeng
Corresponding author
yy62721@sina.com

Corresponding author.
Servicio de Urología, Hospital Oncológico de la Universidad Medica de China, Liaoning Cancer Hospital & Institute, Shenyang, China
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (3)
Table 1. Baseline characteristics.
Table 2. Antitumor activity.
Table 3. Treatment-related and immune-related adverse events in the overall population.
Show moreShow less
Abstract
Objective

Tislelizumab, a monoclonal antibody against programed death protein-1 (PD-1), has shown encouraging antitumor activity in urothelial cancer. This study was designed to assess the efficacy and safety of tislelizumab in urotelial cancer in a real-world setting.

Methods

The study was a real-world retrospective study undertaken at Liaoning Cancer Hospital & Institute, China. Eligible patients were ≥18 years. Patients received 200-mg tislelizumab monotherapy intravenously every 3 weeks until the disease progressed to intolerable toxicity. Outcomes included an objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety.

Results

Between March 2020 and December 2022, 33 patients were enrolled. The median follow-up was 10.17 (IQR 5.73–12.47) months. Of all 33 patients, ORR and DCR were 30.30% (95% CI 15.6%–48.7%) and 42.42% (95% CI 25.48%–60.78%), respectively. The median PFS was 5.73 (95% CI 3.27–13.00) months, with a 12-month PFS rate of 31.90% (95% CI 19.20%–53.00%). The median OS was 17.7 (95% CI 12.80-not reach) months, with a 12-month OS rate of 67.50% (95% CI 52.70%–86.40%). Eleven (33.33%) and 8 (24.24%) experienced ≥grade 3 treatment-related adverse events (TRAEs) and immune-related Aes, respectively. No treatment-related deaths occurred.

Conclusion

The excellent efficacy and controllable safety of tislelizumab in locally advanced or metastatic urothelial cancer suggest that it may be a promising therapeutic option for this population.

Keywords:
Tislelizumab
Urothelial cancer
Efficacy
Safety
Real-world setting
Resumen
Objetivo

El tislelizumab, un anticuerpo monoclonal dirigido contra la proteína 1 de muerte programada (PD-1), ha demostrado una actividad antitumoral prometedora en el cáncer urotelial. Este estudio se diseñó para evaluar la eficacia y la seguridad de tislelizumab en el cáncer urotelial en un entorno real.

Métodos

El presente es un estudio retrospectivo de vida real realizado en el Liaoning Cancer Hospital & Institute (China). Los pacientes elegibles eran adultos de ≥ 18 años. Los pacientes recibieron 200mg tislelizumab en monoterapia por vía intravenosa cada tres semanas hasta la progresión de la enfermedad, la toxicidad intolerable o la suspensión del tratamiento por cualquier otro motivo. Las variables de interés fueron la tasa de respuesta objetiva (TRO), la tasa de control de la enfermedad (TCE), la supervivencia libre de progresión (SLP), la supervivencia global (SG) y la seguridad.

Resultados

Un total de 33 pacientes fueron inscritos entre marzo de 2020 y diciembre de 2022. La mediana de seguimiento fue de 10,17 (RIQ 5,73–12,47) meses. De los 33 pacientes, la TRO y la TCE fueron de 30,30% (IC 95%: 15,6–48,7%) y de 42,42% (IC 95%: 25,48–60,78%), respectivamente. La mediana de SLP fue de 5,73 (IC 95%: 3,27–13,00) meses, con una tasa de SLP a 12 meses de 31,90% (IC 95%: 19,20–53,00%). La mediana de SG fue de 17,7 (IC 95%: 12,80-no alcanzada) meses, con una tasa de SG a 12 meses de 67,50% (IC 95%: 52,70–86,40%); 11 (33,33%) y ocho (24,24%) pacientes experimentaron eventos adversos relacionados con el tratamiento (EAt) y eventos adversos inmunomediados de grado ≥ 3, respectivamente. No se produjo ninguna muerte relacionada con el tratamiento.

Conclusión

La excelente eficacia y la toxicidad controlable de tislelizumab en el cáncer urotelial localmente avanzado o metastásico sugieren que puede ser una opción terapéutica prometedora para esta población.

Palabras clave:
Tislelizumab
Cáncer urotelial
Eficacia
Seguridad
Entorno de vida real

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos